Updates in RSV Prevention

November 17, 2023

In August, the FDA approved the first RSV vaccine for use in pregnant patients. This vaccine is also being studied in the pediatric population in healthy children who are 2-5 years and children with underlying medical conditions who are 5-18 years. Several other RSV vaccines, including mRNA, vector-based, and live attenuated designs, are currently in trials. Additionally, in July, the FDA approved a new monoclonal antibody for the prevention of RSV in infants. This is the first monoclonal antibody to be recommended in almost 25 years.  The antibody will be available for use in the 2023-2024 RSV season. What makes this antibody unique is its long half-life as it is an IM single dose for infants that protects for a 150-day period. There is a question if this antibody will replace the very well-known palivizumab in the future. Furthermore, clesrovimab (MK-1654), is another monoclonal antibody currently in phase 3 studies for RSV prevention. 

Pharmacists must be aware of the clinical data and outcomes regarding the use of these new RSV prevention strategies in the pediatric and pregnant populations. Because the RSV vaccines were FDA-approved for use in ages 60 years and older in May, pharmacists will likely be asked questions about it also. This session will provide pharmacists with up-to-date data regarding the RSV vaccines and monoclonal antibodies clinical trials’ populations and outcomes in the pediatric and pregnant populations.

Target Audience


Pharmacy Technicians

Learning Objectives

Pharmacists learning objectives:

At the conclusion of this activity, pharmacists should be able to:

  1. Describe outcomes from RSV vaccine trials in the pregnant population.
  2. Describe outcomes of nirsevimab for RSV prevention in the pediatric population.
  3. Differentiate between palivizumab and nirsevimab for RSV prophylaxis in infants.


Pharmacy technician learning objectives

At the conclusion of this activity, pharmacy technicians should be able to:

  1. Describe outcomes from RSV vaccine trials in the pregnant population.
  2. Describe outcomes of nirsevimab for RSV prevention in the pediatric population.

Additional Information

Course summary
Available credit: 
  • 1.50 ACPE Pharmacist
  • 1.50 ACPE Pharmacy Technician
  • 1.50 General CE - Attendance
Course opens: 
Course expires: 
Event starts: 
11/17/2023 - 1:00pm CST
Event ends: 
11/17/2023 - 2:30pm CST


M. Petrea Cober, PharmD, BCNSP, BCPPS, FASPEN
​​Professor – Pharmacy Practice, Director of Professional Development, Director of Workforce Development​
Northeast Ohio Medical University, College of Pharmacy

Lea S. Eiland, Pharm.D., BCPS, BCPPS, FASHP, FPPA
​​Clinical Professor and Associate Department Head​
Auburn University Harrison College of Pharmacy


Planning committee

Gretchen Brummel, PharmD, BCPS (Course Director) 
Pharmacy Executive Director  
Vizient Center for Pharmacy Practice Excellence 
Vizient, Inc. 
Jackie Stokes, BBA 
Manager, Pharmacy Program  
Vizient, Inc. 

John Schoen, PharmD, BCPS
Senior Clinical Manager
Vizient, Inc. 

Identification, Mitigation, and Disclosure of Relevant Financial Relationships

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.


It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.


Disclosure of Relevant Financial Relationships:

Relevant Financial Relationships 

Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.

M. Petrea Cober, PharmD, BCNSP, BCPPS, FASPEN, speaker for this educational activity, is consultant/speaker for BBraun/CAPS; Baxter; Fresenius-Kabi.  She is also a consultant for Wolters-Kluwer.

All relevant financial relationships listed for these individual(s) have been mitigated.

All others in a position to control content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


Statement of Content Validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.


FDA off-label/unapproved usage

Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.

Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.

Evidence-based Content: Low/absence of evidence-based topics are mentioned within this activity

Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.



In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Designation Statement(s):


Vizient, Inc. designates this activity for a maximum of 1.50 ACPE credit hours.

UAN JA0006103-0000-23-339-L01-P

UAN JA0006103-0000-23-339-L01-T



Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation.   Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re- certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.

Available Credit

  • 1.50 ACPE Pharmacist
  • 1.50 ACPE Pharmacy Technician
  • 1.50 General CE - Attendance
Please login or register to take this course.